



Program Pack

EBV (mRNA-1189/95)

EBV has several serious health impacts



**Infectious
mononucleosis**

**Multiple
sclerosis**


Cancer

Epidemiology of EBV and infectious mononucleosis (IM)

EBV infects the vast majority of the world population by adulthood (~95% seropositivity)



Studies in Europe and North America show a more gradual increase in seroprevalence which did not exceed 90% until age 22³





EBV accounts for over 90% of cases of IM⁵. Annual incidence of IM in the general U.S. population is estimated to be at least 45 cases per 100,000⁶ with **peak incidence occurring at ages 15-19y⁷**

Etiologic link between EBV and multiple sclerosis (MS)

Nearly 1M people have MS in the U.S.¹

- EBV seropositivity is nearly universal in MS and seronegative individuals have a negligible risk of MS
- Recent landmark study established a **~32 fold increased risk of developing MS following EBV seroconversion²**
- It was previously established that **infectious mononucleosis** is an MS risk factor, beyond the contribution of EBV alone; in addition, the epidemiology of IM and MS are similar




Sources: 1. <https://www.nationalmssociety.org/About-the-Society/MS-Prevalence> 2. Bjornevik et al <https://www.science.org/doi/10.1126/science.abj8222>; 3. Ascherio A, Munger KL. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update. Semin Neurol. 2016 Apr;36(2):103-14. doi: 10.1055/s-0036-1579693. Epub 2016 Apr 26. PMID: 27116717.


EBV infection is associated with cancer incidence, with increased risk following symptomatic IM

Globally, EBV-associated cancers account for over 200,000 new cases of cancer annually and 150,000 cancer deaths, representing about 1% and 2% of total global cancer incidence and cancer deaths, respectively¹

Association of EBV by indication in the United States




Increased risk following EBV related IM (adjusted risk)⁶




1. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532523/>; 2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518816/>; 3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946499/>; 4. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415781/>; 5. <https://dceg.cancer.gov/research/cancer-types/stomach-gastric/ebv-associated-gastric-cancer>; 6. Risk analyses adjusted for gender, parity, maternal age at delivery, maternal education, maternal residence, and paternal malignancy history. Ref: <https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.991069/full>; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532523/>

Moderna's EBV vaccine candidates could tackle multiple EBV-associated conditions



EBV vaccine (mRNA-1189) encodes for four antigens



EBV (IM): mRNA-1189 Phase 1 trial design; data from Part A

The Phase 1 was designed to test the safety, reactogenicity, and immunogenicity of 4 different dose levels of mRNA-1189 in participants 12-30 years of age



Design

Randomized equally across 4 arms (Part A) and 5 arms (Part B), observer-blind, placebo-controlled study

Number of participants



Part A: 272 EBV seronegative and EBV seropositive healthy adults (18-30 years old)

Part B: 150 healthy EBV seronegative adolescents (12-17 years old)



Vaccination schedule

Three doses of mRNA-1189 (0-2-6 month) or placebo



Duration: 18-months

Enrollment period: December 2021–Oct 2023

Study participants will be followed up for 12 months after study injection



Site location

US

Part A

Cohort 1 (Dose A)

N=68

Cohort 2 (Dose B)

N=68

Cohort 3 (Dose C)

N=68

Cohort 4 (Placebo)

N=68

Part B

Cohort 1 (Dose A)

N=30

Cohort 2 (Dose B)

N=30

Cohort 3 (Dose C)

N=30

Cohort 4 (Dose D)


N=30

Cohort 5 (Placebo)


N=30

mRNA-1189 was observed to be generally well tolerated following 3 injections

- mRNA-1189 was observed to be generally well tolerated in the Phase 1 study
- The low dose group exhibited the lowest rate of systemic reactogenicity
- The frequency and severity of systemic SARs increased after the second and third injections regardless of EBV serostatus
- **Local reactogenicity:**
pain was the most common local reaction at injection site, with frequency similar to other mRNA vaccines



gHgL binding antibody titers elicited by mRNA-1189 are numerically higher than those induced by natural infection




Binding antibody titers to gHgL increased after each injection in both EBV seronegatives and EBV seropositives

There was no obvious dose response after 3 injections, regardless of serostatus

After 3 injections, gHgL titers in seronegative recipients were numerically higher than those in EBV seropositives at baseline

gp42 binding antibody titers elicited by mRNA-1189 are numerically higher than those induced by natural infection




Data from mRNA-1189-P101 Part A (Adults 18-30Y)

Binding antibody titers to gp42 increased after each injection in both EBV seronegatives and EBV seropositives

There was no obvious dose response after 3 injections, regardless of serostatus

After 3 injections, gp42 titers in seronegative recipients were numerically higher than those in EBV seropositives at baseline

gp220 binding antibody titers elicited by mRNA-1189 are numerically higher than those induced by natural infection




Data from mRNA-1189-P101 Part A (Adults 18-30Y)

Binding antibody titers to gp220 increased after each injection in EBV seronegatives while the fold rise was less obvious in EBV seropositives with the 2nd and 3rd injection

There was no obvious dose response after 3 injections, regardless of serostatus

After 3 injections, gp220 titers in seronegative recipients were numerically higher than those in EBV seropositives at baseline

B cell neutralizing antibody titers elicited by mRNA-1189 are numerically higher than those induced by natural infection



Data from mRNA-1189-P101 Part A (Adults 18-30Y)

B cell nAbs were below detection in all EBV seronegative and most EBV seropositive participants at baseline, indicating a low response even in previously infected healthy individuals

Regardless of serostatus, participants across mRNA-1189 dose groups showed increases in B-cell nAbs from Baseline following 3 injections

Though titers were similar across the 3 dose levels, the highest titers were observed in the highest dose group


A larger impact of the 3rd injection on B cell nAbs was noted in the EBV seronegative group compared to the EBV seropositive group

Pooled mRNA-1189 dose levels were observed to reduce viral shedding as compared to placebo


Due to small sample size, results across the three mRNA-1189 dose levels were consolidated and analyzed together to provide better qualitative description of the viral shedding data

At each timepoint, all dose levels of mRNA-1189 delivered a measurable reduction in detectable EBV viral DNA in saliva sampled at monthly intervals when compared to placebo

Though limited in sample size, this impact continues to be observed at 6 months (D337) and 1 year (D505) after the last injection



Moderna's EBV vaccine candidates could tackle multiple EBV-associated conditions



EBV vaccine (mRNA-1195) Phase 1 part A trial design; fully enrolled

The Phase 1 Part A was designed to test the safety, reactogenicity, and immunogenicity of mRNA-1195 (4 different dose levels) in healthy EBV seropositive participants 18-55 years of age



Design

Randomized equally across 10 arms, observer-blind, placebo-controlled study



Number of participants

350 healthy EBV seropositive adults (18-55 years old)



Vaccination schedule

Three doses of mRNA-1195 (0-2-6 month) or placebo



Duration: 12-months

Enrollment period: Apr – Jul 2023

Study participants will be followed up for 6 months after study injection



Site location

US

Part A (18-55 Y)

Total N = 350

Randomization Ratio = 1:1:1:1:1:1:1:1:1:1

Cohort 1 (1195.1; Dose A)	Cohort 2 (1195.2; Dose A)
N=35	N=35
Cohort 3 (1195.1; Dose B)	Cohort 4 (1195.2; Dose B)
N=35	N=35
Cohort 5 (1195.1; Dose C)	Cohort 6 (1195.2; Dose C)
N=35	N=35
Cohort 7 (1195.1; Dose D)	Cohort 8 (1195.2; Dose D)
N=35	N=35
Cohort 9 (1189; Dose E)	Cohort 10 (Placebo)
N=35	N=35

EBV vaccine summary and next steps

Disease burden

- EBV infects more than 90% of the world's adult population; it causes serious health conditions including infectious mononucleosis, several cancers and autoimmune disorders like multiple sclerosis

Safety

- mRNA-1189 is generally well tolerated in adults 18-30 yrs

Immunogenicity

- Phase 1 interim analysis data from mRNA-1189 demonstrate binding antibody titers for glycoproteins (gHgL, gp42, gp220) were boosted regardless of serostatus
- Regardless of serostatus, participants across mRNA-1189 dose groups showed increases in B-cell nAbs from Baseline following 3 injections
- Following 3 injections, titers in mRNA-1189 recipients crossed baseline EBV seropositive threshold
- mRNA-1189 reduced measurable viral shedding in saliva of EBV seropositive recipients

Next steps

- mRNA-1189: in ongoing Phase 2 study
- mRNA-1195: in ongoing Phase 2 study

Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: development candidate activities and clinical trials; the potential for Moderna's EBV vaccines to prevent infectious mononucleosis and to address EBV sequelae; and expected market opportunity. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include those described in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date referenced on the first page.